Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Adv Pharm Technol Res. 2012 Oct;3(4):202-9. doi: 10.4103/2231-4040.104710.

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.

Author information

  • 1Department of Pharmacology, S.D.M.College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India.

Abstract

Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress, however, a significant number of patients still develop CINV, particularly during the 2-5-day period (delayed emesis) following chemotherapy. There is evidence that this may be an underappreciated problem on the part of some caregivers. Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists, and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory approval in the U.S. Both represent useful additions to the therapeutic armamentarium for the management of CINV.

KEYWORDS:

Antiemetics; cancer; chemotherapy; nausea; vomiting

PMID:
23378940
[PubMed]
PMCID:
PMC3560125
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk